Laura Knoblauch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Laura Knoblauch has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Alex Inskip
Population Health Sciences Institute, Newcastle University, National Institute for Health and Care Research (NIHR) Innovation Observatory, Newcastle, NE1 7RU, UK
3 shared publications- Blanca Iciar Indave
World Health Organization, International Agency for Research on Cancer, Lyon, 69366, France
3 shared publications - Dilani Lokuhetty
World Health Organization, International Agency for Research on Cancer, Lyon, 69366, France
3 shared publications Elena Plans-Beriso
National Center for Epidemiology, Instituto de Salud Carlos III, Department of Epidemiology of Chronic Diseases, Madrid, 28029, Spain
3 shared publicationsFiona Campbell
University of Birmingham, Centre for Evidence and Implementation Science, Birmingham, B15 2RT, UK
3 shared publications- Harshima Disvini Wijesinghe
World Health Organization, International Agency for Research on Cancer, Lyon, 69366, France
3 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by CERN in Open Research Europe
Mapping the evidence base of kidney, prostate and urinary tract tumours to inform the WHO classification of tumours
Background The project ‘World Health Organization (WHO) Classification of Tumours (WCT): a Living Evidence Gap Map by Tumour Type’ applies the Evidence and Gap Map (EGM) methodology to systematically synthesise evidence to support iterative refinements of the WCT. As part of this work, we created the first EGM for the WCT of Urinary and Male Genital Tumors, covering clear cell renal cell carcinoma, non-clear cell renal cell carcinoma, glandular neoplasms of the prostate and urothelial tumours. Methods Systematic searches in PubMed and Ovid Embase were conducted and harmonised to a 2020 to 2024 publication time period. Following title and abstract screening, reviewers coded and extracted data from the included records for tumour type, characteristic and study design using EPPI-Reviewer®. Levels of evidence were assigned applying the adapted Hierarchy of Research Evidence for Tumour Pathology and visualised with EPPI-Mapper®. Results Of 65,686 deduplicated records, 4,138 studies met inclusion criteria, generating 6,117 EGM entries across 30 tumour types. Evidence on histopathology (28.9%) and prognosis (28.2%) dominated the entries, while prediction was underrepresented (1.6%) or absent in several tumour types. High-level evidence accounted for 17.3% of entries overall, while low-level evidence prevailed across all groups (40.9% in urothelial tumours to 68.0% in non-clear cell renal cell carcinomas). Overall, of 180 tumour-type-by-characteristic EGM cells, 24.4% showed absolute gaps, 42.8% relative gaps, 2.8% synthesis gaps and 30.0% solid evidence. Conclusions The available evidence for urinary tract and male genital tumours is heterogeneous, with robust research in clear cell renal cell carcinoma contrasting with sparse predictive evidence and absolute gaps for rare and recently introduced tumour types. This map highlights targeted systematic reviews, cancer registry-based case accumulation and standardised use of WCT nomenclature as priorities for strengthening urological tumour classification.
- 29 September 2026
- Published by CERN in Open Research Europe
Open AccessMapping the evidence base of kidney, prostate and urinary tract tumours to inform the WHO classification of tumours
Background The project ‘World Health Organization (WHO) Classification of Tumours (WCT): a Living Evidence Gap Map by Tumour Type’ applies the Evidence and Gap Map (EGM) methodology to systematically synthesise evidence to support iterative refinements of the WCT. As part of this work, we created the first EGM for the WCT of Urinary and Male Genital Tumors, covering clear cell renal cell carcinoma, non-clear cell renal cell carcinoma, glandular neoplasms of the prostate and urothelial tumours. Methods Systematic searches in PubMed and Ovid Embase were conducted and harmonised to a 2020 to 2024 publication time period. Following title and abstract screening, reviewers coded and extracted data from the included records for tumour type, characteristic and study design using EPPI-Reviewer®. Levels of evidence were assigned applying the adapted Hierarchy of Research Evidence for Tumour Pathology and visualised with EPPI-Mapper®. Results Of 65,686 deduplicated records, 4,138 studies met inclusion criteria, generating 6,117 EGM entries across 30 tumour types. Evidence on histopathology (28.9%) and prognosis (28.2%) dominated the entries, while prediction was underrepresented (1.6%) or absent in several tumour types. High-level evidence accounted for 17.3% of entries overall, while low-level evidence prevailed across all groups (40.9% in urothelial tumours to 68.0% in non-clear cell renal cell carcinomas). Overall, of 180 tumour-type-by-characteristic EGM cells, 24.4% showed absolute gaps, 42.8% relative gaps, 2.8% synthesis gaps and 30.0% solid evidence. Conclusions The available evidence for urinary tract and male genital tumours is heterogeneous, with robust research in clear cell renal cell carcinoma contrasting with sparse predictive evidence and absolute gaps for rare and recently introduced tumour types. This map highlights targeted systematic reviews, cancer registry-based case accumulation and standardised use of WCT nomenclature as priorities for strengthening urological tumour classification.
- Open Access
- 30 June 2026
- Published by CERN in Open Research Europe
- Vol. 6, 224
Mapping the evidence base of kidney, prostate and urinary tract tumours to inform the WHO classification of tumours
Background The project ‘World Health Organization (WHO) Classification of Tumours (WCT): a Living Evidence Gap Map by Tumour Type’ applies the Evidence and Gap Map (EGM) methodology to systematically synthesise evidence to support iterative refinements of the WCT. As part of this work, we created the first EGM for the WCT of Urinary and Male Genital Tumors, covering clear cell renal cell carcinoma, non-clear cell renal cell carcinoma, glandular neoplasms of the prostate and urothelial tumours. Methods Systematic searches in PubMed and Ovid Embase were conducted and harmonised to a 2020 to 2024 publication time period. Following title and abstract screening, reviewers coded and extracted data from the included records for tumour type, characteristic and study design using EPPI-Reviewer®. Levels of evidence were assigned applying the adapted Hierarchy of Research Evidence for Tumour Pathology and visualised with EPPI-Mapper®. Results Of 65,686 deduplicated records, 4,138 studies met inclusion criteria, generating 6,117 EGM entries across 30 tumour types. Evidence on histopathology (28.9%) and prognosis (28.2%) dominated the entries, while prediction was underrepresented (1.6%) or absent in several tumour types. High-level evidence accounted for 17.3% of entries overall, while low-level evidence prevailed across all groups (40.9% in urothelial tumours to 68.0% in non-clear cell renal cell carcinomas). Overall, of 180 tumour-type-by-characteristic EGM cells, 24.4% showed absolute gaps, 42.8% relative gaps, 2.8% synthesis gaps and 30.0% solid evidence. Conclusions The available evidence for urinary tract and male genital tumours is heterogeneous, with robust research in clear cell renal cell carcinoma contrasting with sparse predictive evidence and absolute gaps for rare and recently introduced tumour types. This map highlights targeted systematic reviews, cancer registry-based case accumulation and standardised use of WCT nomenclature as priorities for strengthening urological tumour classification.
- 30 June 2026
- Published by CERN in Open Research Europe
- Vol. 6, 224
Open AccessMapping the evidence base of kidney, prostate and urinary tract tumours to inform the WHO classification of tumours
Background The project ‘World Health Organization (WHO) Classification of Tumours (WCT): a Living Evidence Gap Map by Tumour Type’ applies the Evidence and Gap Map (EGM) methodology to systematically synthesise evidence to support iterative refinements of the WCT. As part of this work, we created the first EGM for the WCT of Urinary and Male Genital Tumors, covering clear cell renal cell carcinoma, non-clear cell renal cell carcinoma, glandular neoplasms of the prostate and urothelial tumours. Methods Systematic searches in PubMed and Ovid Embase were conducted and harmonised to a 2020 to 2024 publication time period. Following title and abstract screening, reviewers coded and extracted data from the included records for tumour type, characteristic and study design using EPPI-Reviewer®. Levels of evidence were assigned applying the adapted Hierarchy of Research Evidence for Tumour Pathology and visualised with EPPI-Mapper®. Results Of 65,686 deduplicated records, 4,138 studies met inclusion criteria, generating 6,117 EGM entries across 30 tumour types. Evidence on histopathology (28.9%) and prognosis (28.2%) dominated the entries, while prediction was underrepresented (1.6%) or absent in several tumour types. High-level evidence accounted for 17.3% of entries overall, while low-level evidence prevailed across all groups (40.9% in urothelial tumours to 68.0% in non-clear cell renal cell carcinomas). Overall, of 180 tumour-type-by-characteristic EGM cells, 24.4% showed absolute gaps, 42.8% relative gaps, 2.8% synthesis gaps and 30.0% solid evidence. Conclusions The available evidence for urinary tract and male genital tumours is heterogeneous, with robust research in clear cell renal cell carcinoma contrasting with sparse predictive evidence and absolute gaps for rare and recently introduced tumour types. This map highlights targeted systematic reviews, cancer registry-based case accumulation and standardised use of WCT nomenclature as priorities for strengthening urological tumour classification.
- Open Access
- 10 June 2026
- Published by CERN in Open Research Europe
- Vol. 6, 198
Mapping evidence and gaps in diagnostic characteristics of endometrial carcinomas of the uterine corpus: implications for the WHO Classification of tumours, research, and clinical practice
Objective The project “Mapping the Evidence for the World Health Organization (WHO) Classification of Tumours: a Living Evidence Gap Map by Tumour Type, WCT EVI MAP” pioneered use of Evidence Gap Maps (EGMs) in pathology to support future WHO Tumour Classification (WCT) editions. In this study, we generated an EGM for endometrial carcinomas of the uterine corpus (ECUC). Methods Structured PubMed and Ovid Embase searches and title and abstract screening identified peer-reviewed primary studies and systematic reviews addressing diagnostic characteristics, pathogenesis, diagnostic imaging, histopathology including cytopathology, diagnostic molecular pathology, prognosis, and prediction of therapy response for endometrioid, serous, clear cell, undifferentiated/dedifferentiated, mixed, and other endometrial carcinomas, and carcinosarcomas of the uterine corpus published between 01/01/2020 and 27/08/2024. Eligible abstracts reported sufficient methodological detail and effect measures disaggregated by WCT-aligned tumour type. Purely preclinical, qualitative, in silico, omics database-derived, treatment-effectiveness, and relapse/recurrence/metastasis studies were excluded. Included studies were coded by tumour characteristics, tumour types, and study design-related evidence levels according to a predefined hierarchy (1–highest, 5–lowest). Results Of 11,165 screened studies, 698 were included, yielding 1,134 map entries. Histopathology was most frequently investigated (44.4%), followed by prognosis (29.5%), whereas prediction studies were rare (0.8%). Level 1–2 evidence was concentrated in prognosis (60.3%), while other domains were mainly supported by level ≤ 3 evidence. Systematic reviews represented 0.7% of included studies, and 70% focused on prognosis. Conclusions Histopathology is the best-supported ECUC characteristic. Evidence on treatment-response prediction remains limited, even for endometrioid carcinomas. For non-endometrioid ECUC, evidence on pathogenesis and diagnostic imaging is sparse, and molecular pathology studies are more common but mostly low-level. Major synthesis gaps remain, with systematic reviews largely restricted to prognosis. High-level primary studies and systematic reviews are needed, particularly for pathogenesis, diagnostic imaging, predictive biomarkers, and rare ECUC subtypes, to inform WCT updates and improve diagnosis.
- 10 June 2026
- Published by CERN in Open Research Europe
- Vol. 6, 198
Open AccessMapping evidence and gaps in diagnostic characteristics of endometrial carcinomas of the uterine corpus: implications for the WHO Classification of tumours, research, and clinical practice
Objective The project “Mapping the Evidence for the World Health Organization (WHO) Classification of Tumours: a Living Evidence Gap Map by Tumour Type, WCT EVI MAP” pioneered use of Evidence Gap Maps (EGMs) in pathology to support future WHO Tumour Classification (WCT) editions. In this study, we generated an EGM for endometrial carcinomas of the uterine corpus (ECUC). Methods Structured PubMed and Ovid Embase searches and title and abstract screening identified peer-reviewed primary studies and systematic reviews addressing diagnostic characteristics, pathogenesis, diagnostic imaging, histopathology including cytopathology, diagnostic molecular pathology, prognosis, and prediction of therapy response for endometrioid, serous, clear cell, undifferentiated/dedifferentiated, mixed, and other endometrial carcinomas, and carcinosarcomas of the uterine corpus published between 01/01/2020 and 27/08/2024. Eligible abstracts reported sufficient methodological detail and effect measures disaggregated by WCT-aligned tumour type. Purely preclinical, qualitative, in silico, omics database-derived, treatment-effectiveness, and relapse/recurrence/metastasis studies were excluded. Included studies were coded by tumour characteristics, tumour types, and study design-related evidence levels according to a predefined hierarchy (1–highest, 5–lowest). Results Of 11,165 screened studies, 698 were included, yielding 1,134 map entries. Histopathology was most frequently investigated (44.4%), followed by prognosis (29.5%), whereas prediction studies were rare (0.8%). Level 1–2 evidence was concentrated in prognosis (60.3%), while other domains were mainly supported by level ≤ 3 evidence. Systematic reviews represented 0.7% of included studies, and 70% focused on prognosis. Conclusions Histopathology is the best-supported ECUC characteristic. Evidence on treatment-response prediction remains limited, even for endometrioid carcinomas. For non-endometrioid ECUC, evidence on pathogenesis and diagnostic imaging is sparse, and molecular pathology studies are more common but mostly low-level. Major synthesis gaps remain, with systematic reviews largely restricted to prognosis. High-level primary studies and systematic reviews are needed, particularly for pathogenesis, diagnostic imaging, predictive biomarkers, and rare ECUC subtypes, to inform WCT updates and improve diagnosis.
- Open Access
- 2 January 2026
- Published by SAGE Publications in Tumor Biology
- Vol. 48
Tumour markers and evidence-based pathology
Background: Tumour biomarkers have become increasingly important in oncology, shaping cancer diagnostics, classification, and patient management. Despite their potential, the use of cancer biomarkers in clinical settings remains limited. Objective: This paper aims to outline biomarker development, from classical, serum protein markers to emerging tumour biomarkers, including meta-biomarkers, to show their diversity and point out the challenges in their development, reporting, and implementation in clinical practice as well as their relevance in evidence-based pathology and cancer classification. Methods: A literature-based analysis, incorporating insights from our ongoing research, is presented. Results: Although numerous potential biomarkers, biomarker signatures, and meta-biomarkers, are being discovered, existing innovations are often not supported by sufficiently rigorous research methodologies and standardised reporting practices to enable their translation into clinical practice. Conclusions: To ensure that biomarker discoveries are both scientifically sound and clinically useful, improved research and validation methods, along with adherence to established reporting standards, are essential. We propose the use of the Hierarchy of Evidence for Tumour Pathology as a framework to evaluate and map existing evidence and identify knowledge gaps and research priorities.
- 2 January 2026
- Published by SAGE Publications in Tumor Biology
- Vol. 48
Open AccessTumour markers and evidence-based pathology
Background: Tumour biomarkers have become increasingly important in oncology, shaping cancer diagnostics, classification, and patient management. Despite their potential, the use of cancer biomarkers in clinical settings remains limited. Objective: This paper aims to outline biomarker development, from classical, serum protein markers to emerging tumour biomarkers, including meta-biomarkers, to show their diversity and point out the challenges in their development, reporting, and implementation in clinical practice as well as their relevance in evidence-based pathology and cancer classification. Methods: A literature-based analysis, incorporating insights from our ongoing research, is presented. Results: Although numerous potential biomarkers, biomarker signatures, and meta-biomarkers, are being discovered, existing innovations are often not supported by sufficiently rigorous research methodologies and standardised reporting practices to enable their translation into clinical practice. Conclusions: To ensure that biomarker discoveries are both scientifically sound and clinically useful, improved research and validation methods, along with adherence to established reporting standards, are essential. We propose the use of the Hierarchy of Evidence for Tumour Pathology as a framework to evaluate and map existing evidence and identify knowledge gaps and research priorities.